Abivax (AAVXF) EBT (2022 - 2026)

Abivax has reported EBT for 5 years, with the latest figure at -$56.5 million in Q1 2026.

• On a quarterly basis, EBT fell 2.52% year-over-year to -$56.5 million in Q1 2026; TTM through Mar 2026 was -$379.2 million, a 89.99% decrease from a year earlier, with the FY2025 full-year figure at -$384.4 million, down 104.12% from the prior year.
• EBT was -$56.5 million for Q1 2026 at Abivax, up from -$88.6 million in the prior quarter.
• The five-year high for EBT was -$41.8 million in Q2 2024, with the low at -$179.3 million in Q3 2025.
• Average EBT over 5 years is -$75.3 million, with a median of -$56.5 million recorded in 2026.
• The sharpest annual moves came in 2024 and 2025: EBT surged 69.3% in 2024, then sank 195.6% in 2025.
• Over 5 years, EBT stood at -$66.1 million in 2022, then plunged by 107.34% to -$137.1 million in 2023, then jumped by 69.3% to -$42.1 million in 2024, then slumped by 110.55% to -$88.6 million in 2025, then jumped by 36.25% to -$56.5 million in 2026.
• The last three EBT figures came in at -$56.5 million (Q1 2026), -$88.6 million (Q4 2025), and -$179.3 million (Q3 2025), per Business Quant data.